ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2173

Impact of Smoking on Patient-Reported Disease Status and Symptoms Among Women with Lupus

Patricia P. Katz1, Eliza Chakravarty2, Robert S. Katz3 and Kaleb Michaud4, 1Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Rush University Medical Center, Chicago, IL, 4Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: ARHP III: Epidemiology and Public Health

Session Type: ARHP Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Smoking appears to be associated both with an increased risk of rheumatoid arthritis and with more severe symptoms.  The impact of smoking on patient-reported disease status and symptoms in lupus has not been reported.

Methods:  Data were from the National Data Bank for Rheumatic Diseases (NDB), for which participants complete questionnaires every 6 months.  Only women with lupus who responded to at least one of the two most recent completed questionnaires were included (n = 481).  Self-reported lupus status was assessed with the Systemic Lupus Activity Questionnaire (SLAQ)1, the Brief Inventory of Lupus Damage (BILD)2, global assessment of health status (rating from 0 [doing very well] – 10 [doing very poorly]), and assessment of lupus activity (rating from 0 [not active] – 10 [very active]).  Patient-reported symptoms were assessments of pain, fatigue, and sleep problems, each rated 0 – 10 with higher ratings reflecting worse symptoms, and depressive symptoms assessed with the PHQ-8.  Bivariate and multivariate linear regression analyses estimated the relationship of current and former smoking on outcomes.  Multivariate analyses controlled for age, low education, Medicaid or no health insurance, number of rheumatology visits, duration of lupus, obesity, Rheumatic Disease Comorbidity Index (RDCI)3, and prednisone use.

Results: Mean age was 58 ± 13 years, 22% had education ≤ high school, and 15% had Medicaid or no health insurance.  Mean disease duration was 21 ± 12 years, 34% were obese, and mean score on the RDCI was 2.7 ± 1.8.  Means of each lupus status and symptom measure are shown in the Table.  Six percent were current smokers, 31% were former smokers, and 63% had never smoked.  In unadjusted analyses, current smokers had significantly worse scores than never smokers on all measures except the BILD (Table), and former smokers had worse scores on the SLAQ and ratings of lupus activity.  After adjustment, the elevated scores of current smokers compared with never smokers remained for all measures except the BILD.

Conclusion: While current smoking was not common, it was associated with significantly worse patient assessments of lupus status and worse symptoms.  Findings underscore the importance of assessing smoking and supporting smoking cessation efforts among women with lupus.

1 Karlson EW, et al.  Lupus 2003; 12:280.

2 Yazdany J, et al. Arthritis Care Res 2011; 63:1170

3 England BR, et al. Arthritis Care Res 2015; 6: 865

 

Table.  Association of current and former smoking with patient-reported lupus status and symptoms

 

Overall mean ± SD

Smoking

Unadjusted*

Adjusted*

Global assessment of lupus

(0 – 10 rating, higher score worse)

4.12 ± 2.57

Current

Former

Never

5.77 (.003)

4.08 (.22)

3.70 (ref)

5.55 (.004)

3.98 (.35)

3.75 (ref)

Lupus disease activity (Systemic Lupus Activity Questionnaire; SLAQ)

11.05 ± 7.14

Current

Former

Never

17.13 (.006)

12.26 (.03)

10.06 (ref)

16.89 (.004)

11.80 (.17)

10.25 (ref)

Lupus disease damage (Brief Inventory of Lupus Damage; BILD)

3.32 ± 2.08

Current

Former

Never

4.00 (.25)

3.65 (.09)

3.14 (ref)

3.79 (.21)

3.38 (.69)

3.27 (ref)

Lupus activity (0 – 100 rating, higher score worse)

30.04 ± 27.45

Current

Former

Never

52.50 (.009)

35.92 (.02)

26.74 (ref)

50.54 (.01)

34.84 (.09)

27.25 (ref)

Pain (0 – 10 rating, higher score worse)

4.30 ± 2.99

Current

Former

Never

6.04 (.01)

4.13 (.51)

3.90 (ref)

5.80 (.02)

4.08 (.82)

3.95 (ref)

Fatigue (0 – 10 rating, higher score worse)

5.15 ± 3.13

Current

Former

Never

6.85 (.03)

4.95 (.95)

4.93 (ref)

6.67 (.03)

5.01 (.82)

4.91 (ref)

Sleep problems (0 – 10 rating, higher score worse)

4.35 ± 3.21

Current

Former

Never

7.62 (<.0001)

4.35 (.49)

4.08 (ref)

7.38 (.0002)

4.36 (.42)

4.08 (ref)

Depressive symptoms (PHQ8)

5.92 ± 5.39

Current

Former

Never

11.12 (.003)

6.54 (.12)

5.38 (ref)

10.99 (.002)

6.41 (.24)

5.45 (ref)

* Unadjusted and adjusted means (p-values) calculated from linear regression analyses.  Multivariate analyses controlled for age, duration of lupus, low education, Medicaid or no insurance, obesity, comorbidities, prednisone use, and number of rheumatologist visits, comparing current and former smokers to never smokers.


Disclosure: P. P. Katz, None; E. Chakravarty, None; R. S. Katz, None; K. Michaud, None.

To cite this abstract in AMA style:

Katz PP, Chakravarty E, Katz RS, Michaud K. Impact of Smoking on Patient-Reported Disease Status and Symptoms Among Women with Lupus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/impact-of-smoking-on-patient-reported-disease-status-and-symptoms-among-women-with-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-smoking-on-patient-reported-disease-status-and-symptoms-among-women-with-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology